louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00528502: Lidocaine Supplement for Minimal Invasive Parathyroid Surgery
Official title: Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Parathyroid Disease
Keywords: Parathyroid Disease
Minimal Invasive Parathyroid Surgery
MIPS
Laryngeal Reflexes
Lidocaine
Saline
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2007-09-12
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objective:

1. To determine if the application of lidocaine to the airway will obtund or abolish the laryngeal reflexes. This in turn will lead to a quiescent controlled surgical field.

Detailed description: Lidocaine is a local anesthetic that causes numbness to the throat when misted into the air. This numbness in the throat should stop the urge to clear the throat in the middle of the operation. Therefore, this should stop the interruptions during the surgery.

If you agree to take part in this study, you will be randomly assigned (as in the toss of a coin) to one of 2 groups. Participants in Group 1 will receive the saline mist. This will moisturize and soothe the throat. Participants in Group 2 will receive the lidocaine mist. Lidocaine or saline is misted into the air that you breathe during the surgery. You and your surgeon will not be told which group you were assigned to. At the end of the surgery, your surgeon will answer some questions to help determine if the use of lidocaine or saline is beneficial.

You will be considered off-study once you are sent to the recovery room after surgery.

This is an investigational study. Lidocaine is FDA-approved and commercially available for local anesthesia. If you are in the lidocaine or the saline group. Up to 105 patients will take part in this study. All will be enrolled at M. D. Anderson.

Eligibility criteria: Inclusion Criteria:

* All outpatients scheduled for MIPS at the ACB by Dr N Perrier, Dr D Evans and Dr JE Lee.

Exclusion Criteria:

* Patients who are excluded will be any who require elective endotracheal intubation as a preoperative decision by the anesthesia team. These patients will be those with sleep apnea, BMI\>35, uncontrolled gastro esophageal reflux.
* Patients who have a history of allergy/hypersensitivity to lidocaine.

Primary outcomes:
measure: Severity of Airway Interruption
timeFrame: Assessment made by surgeon during minimally invasive parathyroidectomy surgery
measure: Quality of Operative Field
timeFrame: Assessment made by surgeon during minimally invasive parathyroidectomy surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Spencer Kee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04415502: CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity
Official title: CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rheumatoid Arthritis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Measuring of CTHRc1 levels and its correlation with RA disease activity

Brief summary: The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity

Detailed description: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Recently, reported increased levels of collagen triple helix repeat containing 1 protein (CTHRC1) are strongly associated with the severity of murine proteoglycan-induced arthritis and collagen antibody-induced murine arthritis (CAIA) , further CTHRC1 expression in murine experimental arthritis is increased in the synovium and specifically detected in activated murine , located at the synovial intimal lining and at the bone-pannus interface .Of interest,The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients .

Eligibility criteria: Inclusion Criteria:

* patients diagnosed as RA
* age more than 18 years

Exclusion Criteria:

* other rheumatological diseases Malignancies Hepatic diseases

Primary outcomes:
measure: CTHRC1 in RA
timeFrame: One year
measure: CTHRc1 and RA disease activity
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Chewick S. Infection control demand administrative support. Dimens Health Serv. 1975 Dec;52(12):40-1. No abstract available.
citation: Lumholtz IB. [Nurses' drug information: therapeutic action group: benzodiazepine derivatives. 2]. Sygeplejersken. 1975 Sep 24;75(38):15. No abstract available. Danish.
Clinical trial NCT03775902: Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development
Official title: Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development in Healthy and Insulin Resistant Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin Resistance
Keywords: skeletal muscle
muscle fatigue
ion handling
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2018-12-14
Enrollment: 16
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: BASIC_SCIENCE

Brief summary: To investigate the role of ATP sensitive K+ potassium channels and the Na+/K+ pump in the development of fatigue in healthy and in insulin resistant subjects.


Eligibility criteria: Inclusion Criteria:

* Non smokers
* HbA1c \<38 mmol/mol (\<5.7%), HOMA-IR \> 1.7 (insulin resistant)
* VO2max \<40 ml/kg/min (insulin resistant), 45-55 ml/kg/m2 (healthy)
* BMI \>26 kg/m2 (insulin resistant), 19-26 kg/m2 (healthy)

Exclusion Criteria:

* Use of antidiabetic medication or any other medication deemed to interfere with study outcomes
* Allergy towards Nicorandil
* Chronic disease other than type 2 diabetes deemed to interfere with study outcomes
* Excessive alcohol consumption (\>14 units/week)
* Abnormal ECG

Primary outcomes:
measure: Extracellular potassium concentration meassured with microdialysis
timeFrame: Changes in potassium handling from the placebo experimental day compared to the experimental days with Nicorandil ingestion with 14 days between each experimental day. Timeframe pr. subject approx. 6 weeks
Secondary outcomes:
measure: Performance (time to exhaustion) during knee extensor exercise
timeFrame: Changes in performance during the placebo experimental day compared to the experimental days with Nicorandil ingestion with 14 days between each experimental day. Timeframe pr. subject approx. 6 weeks.
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: University of Copenhagen
state: Danmark
Study officials:
References:
Clinical trial NCT06781502: Electronic Archive of Internal Medicine for the Treatment of Severe Organ Failure and Liver Transplantation-MITIGO
Official title: Electronic Archive of Internal Medicine for the Treatment of Severe Organ Failure and Liver Transplantation-MITIGO
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Organ Failure, Multiple
LIVER TRANSPLANTATION
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2025-01-17
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients belonging to the U.O. will be enrolled. of the Liver Transplant Program of the IRCCS University Hospital of Bologna (Internal Medicine Unit for the treatment of serious organ failure, U.O. Hepatobiliary and Transplant Surgery, Program Abdominal surgery in end organ failure and in patients with organ transplant), in which a diagnosis of acute or chronic liver disease has been made or undergoing liver transplant, starting from 01/01/2013.

Brief summary: ELECTRONIC ARCHIVE OF INTERNAL MEDICINE FOR THE TREATMENT OF SERIOUS ORGAN FAILURES AND LIVER TRANSPLANTATION

Detailed description: This is an observational, spontaneous, monocentric study with structured data collection from the medical records of patients diagnosed with acute or chronic liver failure. The study will involve both retrospective and prospective data collection:

Retrospective data collection: Patients diagnosed between 01/01/2013 and the start date of the study.

Prospective data collection: Patients diagnosed after the start of the study until the end of the recruitment period (10 years).

Eligibility criteria: Inclusion Criteria:

* Diagnosis of acute or chronic liver disease or LT
* Age ≥ 18 years
* Obtaining informed consent

Exclusion Criteria:

* no one

Primary outcomes:
measure: Epidemiological classification of Acute or Chronic Liver Disease and Liver Transplant Candidates at the U.O. of Internal Medicine
timeFrame: 10 years
measure: Incidence of Complications in Chronic Liver Disease
timeFrame: 10 years
measure: Hospitalization Rates
timeFrame: 10 years
measure: Number of Liver Transplantation Candidates Evaluated
timeFrame: 10 years
measure: Number of Liver Transplants Performed Annually
timeFrame: 10 years
Secondary outcomes:
measure: Description of Prescribed Treatments and Variations for Acute or Chronic Liver Disease and Liver Transplant Candidates at the U.O. of Internal Medicine
timeFrame: 10 years
measure: Survival Rate Quantification
timeFrame: 10 years
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS - Azienda Ospedaliero-Universitaria di Bologna
Study officials:
affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
name: Giovanni Vitale, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05576402: Endoscopic Scoring System Utilization in Inflammatory Bowel Disease
Official title: Endoscopic Scoring System Utilization for Inflammatory Bowel Disease Activity Assessment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Inflammatory Bowel Diseases
Lead sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Sponsor class: OTHER
First posted: 2022-10-12
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients who have already received a diagnosis of either Crohn's disease or ulcerative colitis

Brief summary: Inflammatory bowel diseases comprise two distinctive entities: Crohn's disease and ulcerative colitis. During the last decade, endoscopic assessment of inflammation has become relevant since it is a prognostic factor. As a consequence, therapeutic targets now contemplate mucosal healing as part of the goals to be achieved. Endoscopic scores for Crohn's disease and ulcerative colitis have been developed to objectively assess the mucosal inflammatory activity. Although they may have some limitations, these scores have been widely accepted in referral centers, especially since they have been adopted as standard evaluation in inflammatory bowel disease clinical trials . However, their use in the setting of endoscopic practice outside centers with a high volume or with less experience in clinical trials is not known.


Eligibility criteria: Inclusion Criteria:

* Adult patients who underwent colonoscopy for the evaluation of mucosal inflammatory activity
* Patients with an established diagnosis of either Crohn's disease or ulcerative colitis

Exclusion Criteria:

* Sigmoidoscopies performed in ulcerative colitis for the assessment of mucosal inflammatory activity

Primary outcomes:
measure: Endoscopic score report
timeFrame: January 2018-October 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: CEMIC
Study officials:
affiliation: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
name: Juan S Lasa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01073202: Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Transplantation
Ischemia-reperfusion Injury
Cholestasis
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2010-02-23
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the possible beneficial effects of UDCA on liver graft recovery early after adult liver transplantation.


Eligibility criteria: Inclusion Criteria:

* All liver transplant patients in our center between May 2005 and April 2008 were potentially eligible for enrollment

Exclusion Criteria:

* Age less than 18 years
* Treatment with UDCA within one month before operation
* Inability to provide written informed consent prior to study entry
* Non-liver organ(s) failure prior to entry

Primary outcomes:
measure: Serum liver tests
timeFrame: within the first 4 weeks after liver transplantation
Secondary outcomes:
measure: Postoperative complications
timeFrame: within the first 4 weeks after liver transplantation
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai First People's Hospital
state: Shanghai
Study officials:
affiliation: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
name: Zhi-Hai Peng, MD
role: STUDY_CHAIR
References:
citation: Hertl M, Hertl MC, Kluth D, Broelsch CE. Hydrophilic bile salts protect bile duct epithelium during cold preservation: a scanning electron microscopy study. Liver Transpl. 2000 Mar;6(2):207-12. doi: 10.1002/lt.500060201.
citation: Hertl M, Hertl MC, Kunkel P, Schilling S, Prevot B, Kluth D, Malago M, Broelsch CE. Tauroursodeoxycholate ameliorates reperfusion injury after pig liver transplantation. Transpl Int. 1999;12(6):454-62. doi: 10.1007/s001470050257.
citation: Hertl M, Harvey PR, Swanson PE, West DD, Howard TK, Shenoy S, Strasberg SM. Evidence of preservation injury to bile ducts by bile salts in the pig and its prevention by infusions of hydrophilic bile salts. Hepatology. 1995 Apr;21(4):1130-7.
Clinical trial NCT03447002: Urine Levels of Metanephrin and Normetanephrin in Patients With Frequent Ventricular Premature Complex
Official title: Urine Levels of Metanephrin and Normetanephrin in Patients With Frequent Ventricular Premature Complex
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Premature Ventricular Contraction
Keywords: premature
pvc
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2018-02-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with % 5 or higher frequents premature ventricular complex in 24 hours rhythm recording will be taken our study.

Brief summary: Enhanced automaticity process is the underlying mechanism for arrhythmias due to excess catecholamines. Catecholamines may increase in patients with PVC. Metabolites of catecholamines are metanephrine and normetanephrine. Our aim is to measure 24 hours urine levels of metanephrine and normetanephrine.

Detailed description: Premature ventricular complex is a very frequent arrhythmia. Suggested mechanisms for PVCs are reentry, triggered activity, and enhanced automaticity. Enhanced automaticity process is the underlying mechanism for arrhythmias due to excess catecholamines. Catecholamines may increase in patients with PVC. Half-lives of catecholamines are very short and rather changeable. Therefore, 24 hours urine levels of catecholamines are the more sensitive than plasma levels. Metabolites of catecholamines are metanephrine and normetanephrine. Our aim is to measure 24 hours urine levels of metanephrine and normetanephrine.

Eligibility criteria: Inclusion Criteria:

* PVC's rate is more than % 5 in 24 hours rhythm recording

Exclusion Criteria:

* ischemic heart disease
* hyperthyroidism
* patients with low ejection fraction

Primary outcomes:
measure: metanephrine and normetanephrine levels
timeFrame: about 10 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes university Yilmaz- mehmet öztaşkın heart hospital
Study officials:
References:
citation: Im SI, Park KM, Park SJ, Kim JS, On YK. New electrocardiographic criteria for predicting successful ablation of premature ventricular contractions from the right coronary cusp. Int J Cardiol. 2016 Dec 1;224:199-205. doi: 10.1016/j.ijcard.2016.09.029. Epub 2016 Sep 16.
citation: Bradfield JS, Homsi M, Shivkumar K, Miller JM. Coupling interval variability differentiates ventricular ectopic complexes arising in the aortic sinus of valsalva and great cardiac vein from other sources: mechanistic and arrhythmic risk implications. J Am Coll Cardiol. 2014 May 27;63(20):2151-2158. doi: 10.1016/j.jacc.2014.02.551. Epub 2014 Mar 19.
Clinical trial NCT01468402: Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma
Official title: Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Exposure to Magnetic Field
Uterine Leiomyoma
Keywords: Leiomyoma
uterine artery embolization
magnetic resonance imaging
Lead sponsor: Hospital Israelita Albert Einstein
Sponsor class: OTHER
Collaborators: name: University of Sao Paulo
First posted: 2011-11-09
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women from the Leiomyoma Service, with eligible criteria and chose this kind of treatment between september 2008 and march 2009.

Brief summary: The purpose of this study is to determine predictive factors in the pelvic magnetic resonance in the response of arterial embolization of uterine leiomyoma.

Detailed description: This study followed symptomatic premenopausal women with uterine leiomyoma who underwent uterine artery embolization (UAE). Treatment was accompanied by magnetic resonance imaging of both the volume of the entire uterus and the leiomyomas one month before and six months after UAE. This patients were treated at the Uterine Leiomyoma Sector of the Department of Obstetrics and Gynecology, Medicine College of the University of São Paulo. In this study, the investigators examined 179 leiomyomas in 50 patients.

Eligibility criteria: Inclusion Criteria:

* ultrasound diagnosis of uterine leiomyoma
* presence of symptoms (menorrhalgia and/or pelvic pain)
* indication for UAE(the desire to keep the uterus and/or contraindications for surgery).

Exclusion Criteria:

* malignant genital neoplasms
* pelvic inflammatory disease
* allergy to iodinated contrast
* coagulopathy, renal failure
* vasculitis
* pelvic irradiation
* pregnancy
* subserosal leiomyoma with a pedicle smaller than 50% of diameter of the fibroid.

Primary outcomes:
measure: Leiomyoma reduction in patients who underwent uterine artery embolization
timeFrame: One month before(baseline) and six month after the embolization
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital Israelita Albert Einstein
state: SP
Study officials:
affiliation: Hospital Israelita Albert Einstein
name: Eduardo Zlotnik
role: PRINCIPAL_INVESTIGATOR
References:
citation: Affonso BB, Nasser F, de Jesus Silva SG, Silva MC, Zlotnik E, de Lorenzo Messina M, Baracat EC. [Strategies for reduction of exposure to ionizing radiation in women undergone to uterine fibroid embolization]. Rev Bras Ginecol Obstet. 2010 Feb;32(2):77-81. Portuguese.
citation: Nasser F, Affonso BB, de Jesus-Silva SG, Coelho Dde O, Zlotnik E, Messina Mde L, Baracat EC. [Uterine fibroid embolization in women with giant fibroids]. Rev Bras Ginecol Obstet. 2010 Nov;32(11):530-5. doi: 10.1590/s0100-72032010001100003. Portuguese.